Title
Heterozygous RFX6 protein truncating variants cause Maturity-Onset Diabetes of the Young (MODY) with reduced penetrance

Authors:
Kashyap A Patel¹, Markku Laakso²,³, Alena Stančáková³, Thomas W Laver¹, Kevin Colclough⁴, Matthew B Johnson¹, Jarno Kettunen⁵, Tiinamaija Tuomi⁵,⁶, Miriam Cnop⁷,⁸, Maggie H. Shepherd¹, Sarah E Flanagan¹, Sian Ellard¹, Andrew T Hattersley¹*, Michael N Weedon¹*#

*Joint contribution
# corresponding author - M.N.Weedon@exeter.ac.uk

1) Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
2) Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
3) Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.
4) Department of Molecular Genetics, Royal Devon and Exeter National Health Service Foundation Trust, Exeter, UK
5) Department of Endocrinology, Abdominal Centre, Helsinki University Hospital; Folkhalsan Research Center; and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland
6) Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
7) ULB Center for Diabetes Research, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
8) Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium

Abstract
Finding new genetic causes of monogenic diabetes can help to understand development and function of the human pancreas. We aimed to find novel protein-truncating variants causing Maturity-Onset Diabetes of the Young (MODY), a subtype of monogenic diabetes. We used a combination of next-generation sequencing of MODY cases with unknown aetiology along with comparisons to the ExAC database to identify new MODY genes. In the discovery cohort of 36 European patients, we identified two probands with novel RFX6 heterozygous nonsense variants. RFX6 protein truncating variants were enriched in the MODY discovery cohort compared to the European control population within ExAC (Odds Ratio=130, P=6x10⁻²⁸). We found similar results in non-Finnish European (n=348, OR=26, P=6x10⁻¹⁴) and Finnish (n=80, OR=22, P=5x10⁻¹⁸) replication cohorts. RFX6 heterozygotes had reduced penetrance of diabetes compared to common HNF1A and HNF4A MODY mutations (27%, 70% and 55% at 25 years of age, respectively). Our study demonstrates that heterozygous RFX6 protein truncating variants are a new cause of MODY with reduced penetrance.
Finding the genetic cause of rare familial diabetes (monogenic diabetes) is important as it provides new biological insights into human pancreas development and function, as well as potentially providing novel therapeutic targets with important treatment implications\(^1\). Maturity-Onset Diabetes of Young (MODY) is a sub-type of monogenic diabetes which usually presents under the age of 25 years. Typically, patients are non-obese, non-insulin dependent and have an autosomal dominant inheritance of diabetes\(^2\). Mutations in \textit{HNF1A}, \textit{HNF4A} and \textit{GCK} are the commonest causes of MODY responsible for \(~60\%\) of MODY aetiology\(^1\). Up to \(11\%)\) of MODY patients lack mutations in the known MODY genes suggesting more genetic aetiologies are still to be discovered\(^1\).

It is difficult to discover new genetic causes of MODY. There has been limited recent success in finding new MODY genes. \textit{WFS1} heterozygous variants were recently shown to be a rare cause of MODY in Finnish families\(^3\) and loss-of-function variants in the \textit{APPL1} gene have recently been reported to cause MODY in two families\(^4\). The reason for this limited success is the difficulty of distinguishing monogenic diabetes patients from those with type 1 diabetes\(^5,6\), or from the increasing number of patients with early-onset type 2 diabetes due to rising rates of obesity. Another important reason is the lack of large pedigrees with an autosomal dominant pattern of inheritance of diabetes that do not have an already known genetic cause. This prevents us from performing classical linkage analysis which was used to discover the most common forms of MODY such as \textit{GCK}, \textit{HNF1A} and \textit{HNF4A}\(^7-10\).

Rare-variant association testing is an important step to confirm the pathogenicity of novel variants in monogenic disease\(^11\). Rare-variant association testing particularly for comparing the frequency of novel protein-truncating variants (PTVs) in monogenic cases with unknown aetiology to the frequency in large control cohorts is now possible because of the availability of resources such as ExAC – a database of protein coding variants in large control populations\(^12\). This allows burden testing of the frequency of novel or rare coding variants in diseases of interest and a comparison to rates in controls to identify new genetic causes of monogenic disease.

In this study, we undertook next-generation sequencing of MODY cases with unknown aetiology and compared the frequency of protein truncating variants to large publicly available control cohorts to identify new MODY genes. Our study identified heterozygous \textit{RFX6} protein truncating variants as a new cause of MODY.

**Results**

**Heterozygous \textit{RFX6} protein-truncating variants were identified in MODY patients with unknown aetiology.** To identify patients with novel heterozygous protein truncating variants causing MODY, we first assessed 38 European (non-Finnish) probands with a strong MODY-like phenotype who did not have mutations in the common MODY genes (\textit{GCK}, \textit{HNF1A}, \textit{HNF4A}) when assessed by Sanger sequencing (\textit{Supplementary Table 1}). To exclude the other known/less common causes of monogenic diabetes, these patients underwent comprehensive targeted-next generation sequencing (NGS) for all 29 known monogenic diabetes genes, including the genes for neonatal diabetes, MODY and mitochondrial...
diabetes, lipodystrophy or other forms of syndromic diabetes)\textsuperscript{13} (Supplementary Table 2). We identified two probands with mutations in the known MODY gene \textit{HNF1B}\textsuperscript{13,14}. The analysis of heterozygous PTVs in the 29 genes on the targeted panel identified two unrelated probands with a novel heterozygous nonsense variant in \textit{Regulatory Factor X 6} (\textit{RFX6}) (Family 1 - p.leu292Ter, Family 2 - p.lys351Ter) (Table 1) (Fig. 1) (Supplementary Fig. 1). We did not identify any rare (<1%) missense \textit{RFX6} variants in this cohort. \textit{RFX6} was part of the targeted sequencing panel because recessive \textit{RFX6} variants (missense and/or protein-truncating) are a known cause of syndromic neonatal diabetes\textsuperscript{15}, but heterozygotes were not previously known to have any phenotype.

**Heterozygous \textit{RFX6} protein-truncating variants were enriched in a MODY discovery cohort compared to population controls from ExAC.** We compared the frequency of \textit{RFX6} PTVs in our discovery cohort to a large control population from ExAC\textsuperscript{12}. Neither of the \textit{RFX6} variants from the discovery cohort were present in the 60,706 individuals in ExAC. There were 15 individuals with \textit{RFX6} PTV in the 33,346 ExAC Non-Finnish European control population (Supplementary Table 3). The frequency of the \textit{RFX6} PTVs in the MODY discovery cohort was significantly higher than the ExAC Non-Finnish European control population (5.5\% vs 0.045\%, Odds ratio=130, 95\% CI 28.7-593.6, \textit{P}=6x10\textsuperscript{-28}) (Table 1).

**Heterozygous \textit{RFX6} protein-truncating variants are associated with MODY in a Non-Finnish European replication cohort.** To replicate the findings of our discovery cohort, we then examined 348 non-Finnish European probands who were routinely referred for MODY genetic testing to the Molecular Genetics Laboratory, Exeter, UK and in whom the common causes of MODY were excluded using targeted-NGS assay (Supplementary Table 1). The analysis of heterozygous PTVs identified four unrelated probands with two novel \textit{RFX6} nonsense variants (p.Gln25Ter, p.Arg377Ter) (Supplementary Table 1) (Supplementary Fig. 1). Similarly to the discovery cohort, the MODY replication cohort was enriched for \textit{RFX6} PTVs compared to the ExAC non-Finnish European control population (1.15\% vs 0.045\%, Odds ratio=26, 95\% CI 8.5-78.2, \textit{P}=6x10\textsuperscript{-14}) (Table 1). \textit{RFX6} is well covered in EXAC, except exon 1 where the median coverage is 18X compared to 86X for the remaining exons (http://exac.broadinstitute.org/gene/ENSG00000185002). If we exclude exon 1 from the analysis the association of \textit{RFX6} PTVs with MODY in the replication cohort is maintained (\textit{P}=0.0014). None of the monogenic diabetes patients with mutations in the known genes had \textit{RFX6} PTVs (\textit{n}=131).

**Finnish individuals had ~10-fold higher frequency of \textit{RFX6} PTVs compared to Non-Finnish Europeans due to a founder effect.** The ExAC database showed a relative abundance of \textit{RFX6} PTVs in Finnish-European (15/3305, 0.45\%) compared to non-Finnish European (15/33,346, 0.045\%) (Supplementary Table 3). All of the Finnish individuals in ExAC with \textit{RFX6} PTV had the same variant, p.His293Leufs. To further validate this finding in a larger Finnish control population, we analysed \textit{RFX6} PTVs in 7040 control individuals from the METSIM study\textsuperscript{16}. There were 26 individuals with \textit{RFX6} PTVs in this cohort and all had the p.His293Leufs variant. The frequency of p.His293Leufs was not significantly different from the ExAC Finnish population frequency (0.37\% vs 0.45\%, \textit{P}=0.63) (Supplementary Table 3). The METSIM study has contributed to the ExAC Finnish cohort so to prevent duplication, we used the data from the larger METSIM study for further analysis\textsuperscript{12}. 
The RFX6 p.His293Leufs is strongly enriched in Finnish MODY patients with unknown aetiology. To assess whether the p.His293Leufs variant is a cause of MODY in Finnish patients, we genotyped the RFX6 p.His293Leufs variant in 80 Finnish probands who were routinely referred for MODY genetic testing to Genome Center of Eastern Finland, University of Eastern Finland and did not have mutations in the most common MODY genes (GCK, HNF1A, HNF4A and HNF1B) (Supplementary Table 1). We identified six probands with the p.His293Leufs variant. The frequency of this variant was significantly higher in the Finnish MODY cohort compared to the METSIM controls (7.5% vs 0.37%, Odds ratio=22, 95% CI 8.7-54.7, \( P = 5 \times 10^{-18} \)) (Table 1).

RFX6 PTVs co-segregation with diabetes is consistent with reduced penetrance. To further assess the causality of RFX6 PTVs, we conducted co-segregation analysis in families with genetic data available on more than three affected individuals. We had one family with >3 affected individuals with genetic data (Fig. 1 and Supplementary Fig. 1). The analysis in this large 4 generation pedigree (Family 1) showed that the RFX6 variant p.Leu292Ter co-segregated in 9 out of 10 individuals with diabetes (maximum LOD score = 2.82). One individual without the RFX6 variant had diabetes which is likely to be a phenocopy of type 2 diabetes considering the large pedigree, age of diagnosis and obesity (51 years, BMI 30 kg/m²). There were two family members with an RFX6 variant but with normal HbA1c level at the time of study (18 and 57 years) suggesting that RFX6 PTVs may have reduced penetrance.

RFX6 PTVs showed reduced penetrance compared to HNF1A and HNF4A MODY. To assess the penetrance of RFX6 PTVs for diabetes compared to common causes of MODY, we combined data for all six non-Finnish European proband families. There were 18 RFX6 heterozygotes of whom five had not developed diabetes at study entry. 27% (95% CI 11-58) developed diabetes by the age of 25 years and 78% (95% CI 55-95) by 51 years (Fig. 2). Two out of six probands did not have affected parents at study entry (Supplementary Fig. 1). The penetrance of diabetes for RFX6 heterozygotes was substantially reduced compared to pathogenic variants of HNF1A (70%, 95% CI 67-72 by the age of 25 years and 97%, 95% CI 96-98 by 50 years) and moderately lower than pathogenic variants of HNF4A (55%, 95% CI 50-60 by the age of 25 years and 91%, 95% CI 88-94 by 50 years) (Fig. 2). Similar to European proband families, the Finnish founder RFX6 p.His293Leufs variant also showed reduced penetrance in Finnish families (Supplementary Fig. 2). In a previously reported family with a homozygous p.Arg181Gln RFX6 neonatal diabetes child \( ^{15,17} \), the limited genetic information available on RFX6 heterozygous family members was also suggestive of reduced penetrance of diabetes (Supplementary Fig. 3).

RFX6 PTVs are not associated with type 2 diabetes. The reduced penetrance and later age of onset of diabetes with RFX6 PTVs raised the possibility that these variants may be associated with type 2 diabetes. To assess this, we used freely available data from the Type 2 diabetes Knowledge Portal which contains whole-exome data on type 2 diabetes patients \( ^{18} \). Burden testing of RFX6 PTVs for exome sequencing data from 8373 type 2 diabetes cases and 8466 controls showed no significant association with type 2 diabetes (0.14% vs 0.083%, Odds ratio=1.79, 95% CI 0.7-4.57, \( P = 0.22 \)) (Supplementary Table 2).
Phenotype of RFX6 heterozygotes with diabetes. The median age of diagnosis of diabetes in 13 non-Finnish European heterozygotes was 36 years (IQR 21-41, range 13-64 years) (Table 2). They had a median 15 years (IQR 11-24) of diabetes with median BMI of 24 kg/m² (IQR 23-26). Significant endogenous insulin was present in 10/11 patients at recruitment. 69% (n=9) of patients were treated with insulin (Table 2). There was no history of sulphonylurea sensitivity and they did not have islet autoantibodies (GAD/IA2). All patients had isolated diabetes and there were no reports of the other features of homozygous RFX6 mutations, duodenal or gall bladder atresia. The Finnish RFX6 p.His293Leufs heterozygotes with diabetes (n=8) had similar phenotypes (Supplementary Table 4).

Discussion

Heterozygous RFX6 protein-truncating variants are a new cause of MODY. The RFX6 PTVs are predicted to be pathogenic according to the published guidelines. We identified these variants in unrelated MODY patients in whom the known causes of monogenic diabetes had been excluded. These variants were enriched in Finnish and non-Finnish European MODY probands. They were rare in the respective control cohorts and in patients with type 2 diabetes. We observed co-segregation within pedigrees albeit with reduced penetrance. Finally, these variants are likely to have a functional effect due nonsense mediated decay causing haploinsufficiency. This is further supported by the studies that showed that the homozygous RFX6 PTVs cause neonatal diabetes. In line with higher frequency in the control Finnish population, RFX6 PTVs were ~7 fold higher in Finnish MODY cases compared to European MODY cases. They were responsible for 7.5% MODY cases compared to only ~1% of MODY European cases. This suggests that RFX6 heterozygous PTVs are a relatively common cause of MODY in the Finnish population.

Large-scale control cohorts such as ExAC in combination with next-generation sequencing of well-characterised cases is a useful strategy for identifying new causes of monogenic disease. The very large ExAC database now provides sufficient power for reliable burden testing of rare variants in monogenic disease. This is a particularly useful strategy for genetically heterogenous monogenic diseases as it does not require large pedigrees or linkage analysis. RFX6 PTVs were highly enriched in both discovery and replication cohorts compared to control cohorts, supporting their pathogenicity. The ExAC database has been very useful in identifying benign variants because of an unusually high frequency in the population compared to frequency of the disease in question. However, caution is required for reduced penetrance variants as their frequency can be higher than estimated disease frequency in the general population. RFX6 PTVs are an example where the reduced penetrance explains the higher frequency in control cohorts compared to the estimated frequency of MODY (0.01%) in the general population.

Our study highlights the importance of population specific control and disease cohorts. The frequency of RFX6 PTVs is ~10-fold higher in the Finnish population compared to non-Finnish populations due to a founder effect. It is ~40-fold higher than the estimated MODY frequency in the European population. Based on this data, RFX6 PTVs may be misclassified as benign variants due to this unusually high frequency in control population. However, using a population specific disease cohort, we showed that RFX6 PTVs were enriched in Finnish MODY patients compared to a Finnish control population. In addition, evidence of
the functional impact of this variant (a Finnish neonatal diabetes patient with homozygous p.His293Leufs21) strongly supports its causality. The higher frequency of PTVs in genetic bottleneck population is not unexpected. It has been shown that the Finnish population has a higher burden of genome-wide PTVs (0.5-5%) compared to non-Finnish Europeans and some of these have been associated with disease.

RFX6 protein-truncating variants cause reduced penetrance MODY. The RFX6 PTV heterozygotes showed reduced penetrance for diabetes compared to the more common HNF1A and HNF4A MODY. Only 27% of heterozygotes developed diabetes by age 25 years and 78% by age 51 years. This reduced penetrance explains the lack of complete co-segregation in the RFX6 pedigrees. It also clarifies why diabetes was only reported in the parents or grandparents (obligate heterozygous for functional RFX6 variants) in 7 out of the 12 published recessive RFX6 neonatal diabetes pedigrees. The lack of enrichment of RFX6 PTVs in type 2 diabetes patients compared to control patients further supports RFX6 as cause of a reduced penetrance MODY rather than type 2 diabetes. Our study may have overestimated the penetrance of RFX6 PTVs due to ascertainment bias as MODY genetic testing is commonly considered for patients with a parental history of diabetes. There are other examples of reduced-penetrance MODY mutations such as the recently published HNF4A p.R114W variant. Homozygous PTVs in transcription factors such as NEUROD1 and PDX1 cause neonatal diabetes and, similar to RFX6, heterozygous PTVs in these two genes have been shown to cause reduced penetrance MODY.

There are differences as well as similarities between RFX6 MODY and HNF1A/HNF4A MODY. In contrast to HNF1A and HNF4A MODY patients, RFX6 MODY patients do not show enhanced sensitivity to sulphonylureas and have reduced penetrance. All patients with HNF1A/HNF4A MODY have significant endogenous insulin more than 3-5 years post diagnosis. RFX6 MODY patients showed a similar pattern. However we had one patient who did not have significant endogenous insulin. Similar to HNF1A/HNF4A MODY subtypes, RFX6 MODY patients also lack islet autoantibodies and have isolated diabetes. This suggests that the presence of persistent C-peptide and lack of islet autoantibodies, which is currently used to distinguish common forms of MODY from type 1 diabetes, can also be used to identify RFX6 MODY. However, a similar strategy will not help to distinguish late onset RFX6 MODY from type 2 diabetes. Further studies are needed to understand the pathophysiology of RFX6 MODY.

Our study supports the role of RFX6 in the adult human pancreas. RFX6 is from a family of transcription factors that contains winged-helix DNA binding domains. RFX6 is expressed almost exclusively in the pancreatic islets, small intestine and colon. It acts downstream of NEUROG3, regulates islet cell differentiation and development of the endocrine pancreas. The homozygous RFX6 missense and protein-truncating variants cause syndromic neonatal diabetes (gall bladder aplasia, gut atresia and diabetes) and RFX6 whole-body null mice show phenotypes consistent with human disease and die soon after birth, but the heterozygous whole-body RFX6 mouse has not been reported to develop diabetes. This is not surprising considering the lack of phenotype in heterozygous null mice of HNF1A and HNF1B. Interestingly, the defect in glucose induced insulin secretion was present in the models that are more akin to haploinsufficiency of RFX6 in adult humans. 80% depletion of the RFX6 protein in the adult mouse pancreas in vivo as well as in human beta
cells in vitro showed that this defect was due to reduced expression of ABCC8, GCK and Ca\textsuperscript{2+} channels in beta cells and disruption of calcium mediated insulin secretion\textsuperscript{30,40}. These data support the role of RFX6 in adult beta cells and may explain the cause of diabetes in our patients.

In conclusion, heterozygous RFX6 protein-truncating variants are a novel cause of reduced penetrance MODY.

Methods

Study population:

*Discovery MODY cohort:* The discovery cohort comprises of 38 European probands with strong MODY-like phenotype who did not have mutations in the three most common MODY genes (GCK, HNF1A and HNF4A) (Supplementary Table 1). They were diagnosed <25 years of age, non-obese, had ≥ 3 generation history of diabetes, non-insulin treated or insulin treated with C-peptide > 200 pmol/L (if available), and lacked islet autoantibodies.

*Non-Finnish European replication MODY cohort:* The replication cohort was derived from 474 non-Finnish European routine MODY diagnostic referrals to the Molecular Genetic Laboratory, Exeter, UK. A monogenic aetiology in a known monogenic diabetes gene was identified in 131 patients and the remaining 343 patients with unknown aetiology comprised the replication cohort (Supplementary Table 1).

*Finnish-European MODY cohort:* This cohort consisted of 80 patients who were routinely referred for MODY diagnostic testing to the Genome Center of Eastern Finland, University of eastern Finland in whom no mutation was found in the common MODY genes (GCK, HNF1A, HNF1B and HNF4A) when assessed by Sanger sequencing (Supplementary Table 1). Two of the identified patients with RFX6 mutations participated in the FINNMODY Study (www.botnia-study.org/finnmody) recruiting patients with MODY-like diabetes and their relatives in Finland, and their families were studied.

*Finnish-European control cohort:* Individuals of this cohort were part of the METSIM study (n=7040). They were all males aged 45 to 70 years, randomly selected from the population register of the Kuopio town, Eastern Finland and have been described previously\textsuperscript{16}.

*Cohort of people with pathogenic HNF1A and HNF4A variants:* This cohort included probands and their family members referred to the Molecular Genetics Laboratory, Exeter, UK for MODY genetic testing and were identified to have a pathogenic HNF1A (n=1265) or HNF4A (n=427) variant.

DNA analysis:

*Targeted-next generation sequencing:* The analysis of all known monogenic diabetes genes in European cohorts was conducted using targeted-next generation sequencing as described previously\textsuperscript{19}. The panel included 29 genes in which variants are known to cause monogenic neonatal diabetes, MODY, mitochondrial diabetes, lipodystrophy or other forms of syndromic diabetes\textsuperscript{13}. 
(Supplementary Table 2). The RFX6 PTVs identified by targeted-NGS were confirmed using a gold-standard Sanger sequencing. The essential splice site, nonsense and frameshift variants excluding the last exon were considered protein-truncating variants in this study\(^{12,20}\). The targeted-NGS assay covered 100% bases of the RFX6 coding region >10x read depth for all the samples.

**Sanger sequencing:**
Genomic DNA was extracted from whole blood using standard procedures and the coding region and intron/exon boundaries of the RFX6 gene were amplified by PCR. Amplicons were sequenced using the Big Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington, UK) according to manufacturer’s instructions and reactions were analysed on an ABI 3730 Capillary sequencer (Applied Biosystems, Warrington, UK). Sequences were compared with the reference sequences (NM_173560.3) using Mutation Surveyor v3.24 software (Soft Genetics, State College, PA).

The Finnish-European MODY cohort was analysed for p.His293Leufs variant using Sanger sequencing as described above. Family co-segregation analysis was performed in available family members using a Sanger sequencing assay for the specific RFX6 variant identified in that family.

DNA analysis of the METSiM study has been described before\(^{21}\).

The DNA analysis of the ExAC cohort has been described previously\(^{12}\). >95% bases of the RFX6 coding region was covered with >10x read depth for >90% of samples. The lowest coverage was seen in exon 1 with only 80% of bases having >10x coverage in >50% of samples. We only used high quality filtered variants for the analysis.

**Ethics:**
The study is approved by the North Wales Research Ethics Committee, UK. The FINNMODY study is approved by the Research Ethics committee for Medicine of the Helsinki University Hospital.

**Statistical analysis:**
The chi-squared test was used to compare the frequency of RFX6 PTVs. The penetrance of diabetes was assessed using survival time analysis method. The statistical analysis was conducted using Stata 14 (StataCorp, Texas, USA). Singlepoint non-parametric linkage analyses were performed using MERLIN 1.1.2\(^{41}\). The Z score was converted into a LOD score by use of the Kong and Cox exponential model implemented in MERLIN\(^{41,42}\).

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. K.A.P and M.N.W. researched data and performed statistical analyses. K.A.P. wrote the first draft of the manuscript, which was modified by all authors. All authors contributed to the discussion and reviewed or edited the manuscript. M.N.W. is the
guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgement:
We thank Drs Marc Abramowicz and Julie Desir for sharing genetic information on RFX6 neonatal diabetes family from Brussels.

Funding: K.A.P. has a postdoctoral fellowship funded by the Wellcome Trust (110082/Z/15/Z). S.E.F. has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (105636/Z/14/Z). S.E. and A.T.H. are Wellcome Trust Senior Investigators (WT098395/Z/12/Z), and A.T.H. is also supported by a NIHR Senior Investigator award. M.N.W. is supported by the Wellcome Trust Institutional Strategic Support Fund (WT097835/MF) and the Medical Research Council (MR/M005070/1). MS is supported by the NIHR Exeter Clinical Research Facility. Additional support came from the University of Exeter and the NIHR Exeter Clinical Research Facility. MC is supported by the Fonds National de la Recherche Scientifique (FNRS), Belgium. The FINNMODY Study has been financially supported by the Folkhalsan Research Foundation, Helsinki University Central Hospital Research Foundation, Finnish Diabetes Research Foundation, Finnish Medical Society, Foundation for Pediatric Research, Ahokas Foundation, Diabetes Wellness Foundation. The views expressed are those of the authors and not necessarily those of the Wellcome Trust, the National Health Service, the NIHR, or the Department of Health.

References:

Table 1: Frequency of heterozygous RFX6 protein-truncating variants in all study cohorts and control populations.

<table>
<thead>
<tr>
<th></th>
<th>MODY cohorts, Frequency of RFX6 PTV</th>
<th>Control population, Frequency of RFX6 PTV</th>
<th>Odds ratio (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Finnish European</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery cohort</td>
<td>5.5%</td>
<td>ExAC control population</td>
<td>130 (28.7-593.6)</td>
<td>6x10^{-28}</td>
</tr>
<tr>
<td>Replication cohort</td>
<td>1.15%</td>
<td>ExAC control population</td>
<td>26 (8.5-78.2)</td>
<td>6x10^{-14}</td>
</tr>
<tr>
<td>Finnish European</td>
<td></td>
<td>METSIM control population</td>
<td>22 (8.7-54.7)</td>
<td>5x10^{-18}</td>
</tr>
</tbody>
</table>

Fig. 1: Extended pedigree of family 1 showing inheritance of heterozygous RFX6 p.Leu292Ter (NM_173560.3:c.875T>G) variant. Genotype is shown underneath each symbol; M and N denote mutant and wild-type alleles, respectively. Directly below the genotype is the age of diabetes onset in years, duration in years, BMI and treatment at study entry. Squares represent male family members, and circles represent female members. Black-filled symbols denote patients with diabetes. An arrow denotes the proband in the family. OHA, oral hypoglycaemic agents. *age at recruitment.
Fig. 2: Penetrance of diabetes in people with a heterozygous *RFX6* protein-truncating variant (n=18), pathogenic *HNF1A* variant (n=1265) or *HNF4A* variant (n=427).

Table 2: Clinical characteristics of non-Finnish European patients with diabetes and *RFX6* heterozygous protein-truncating variant (n=13)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years), median (IQR), n=13</td>
<td>36 (21-41)</td>
</tr>
<tr>
<td>Duration of diabetes, median (IQR), n=13</td>
<td>15 (11-24)</td>
</tr>
<tr>
<td>Female, n (%), n=13</td>
<td>11 (85%)</td>
</tr>
<tr>
<td>BMI (kg/m²), median (IQR), n=12</td>
<td>24 (23-26)</td>
</tr>
<tr>
<td>Initial treatment, n (%), n=13</td>
<td></td>
</tr>
<tr>
<td>Diet</td>
<td>3 (23%)</td>
</tr>
<tr>
<td>Oral hypoglycaemic agents</td>
<td>6 (46%)</td>
</tr>
<tr>
<td>Insulin</td>
<td>3 (23%)</td>
</tr>
<tr>
<td>Insulin + Oral hypoglycaemic agents</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>Current treatment, n (%), n=13</td>
<td></td>
</tr>
<tr>
<td>Diet</td>
<td>1 (8%)</td>
</tr>
<tr>
<td>Oral hypoglycaemic agents</td>
<td>3 (23%)</td>
</tr>
<tr>
<td>Insulin</td>
<td>5 (38%)</td>
</tr>
<tr>
<td>Insulin + Oral hypoglycaemic agents</td>
<td>4 (31%)</td>
</tr>
<tr>
<td>HbA1C at recruitment, mmol/mol, median (IQR), n=11</td>
<td>52 (43-83)</td>
</tr>
<tr>
<td>Significant endogenous insulin at recruitment*, n (%)</td>
<td>10 (91%)</td>
</tr>
</tbody>
</table>

* noninsulin treated or insulin treated with urine/blood random C-peptide >200 pmol/l.